Research
Hormonal
GLP1-RA treatment is associated with improvements in restrained eating and emotional eating behavior compared with placebo.
GLP1-RAs may help improve eating behaviors in this population.
StrongSupportsmedium confidence
GLP1-RA treatment was associated with improvements in restrained eating (g = 0.35; P = .002) and emotional eating behavior (g = 0.32; P = .003).
Why this rating
Based on a meta-analysis of randomized clinical trials.
Source
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health
Aureliane C. S. Pierret et al. · JAMA Psychiatry · 2025
DOI 10.1001/jamapsychiatry.2025.0679
Meta-analysisCited 61×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP1-RA treatment is not associated with a significant difference in risk of serious psychiatric adverse events compared with placebo (log[RR] = -0.02; P = .87).Strong
- GLP1-RA treatment is associated with improvements in mental health-related quality of life compared with placebo (g = 0.15; P < .001).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →